FAST and FAST Canada are pleased to announce a grant to UC Davis. David Segal, Ph.D. and his UC Davis lab have received funding to determine if enzyme replacement therapy (ERT) alleviates the symptoms of Angelman syndrome (AS) in animal models. Individuals with Angelman syndrome lack a working copy of the UBE3A gene. The UBE3A
Blog
Rodent Studies of Non-Snord 116 Paternal Ube3a Activation
FAST and FAST Canada are pleased to announce grant funding to David Segal, Ph.D. and his UC Davis lab to investigate targeting the Ube3a-AS (Ube3a Antisense Transcript) without disrupting the expression of Snord116 and Snord115. Dr. Segal’s previously published research has shown that reduction in Ube3a-AS may also reduce expression of Snord116 and Snord115, which
Co-funded Grants with FAST Canada
FAST is proud to co-fund with FAST Canada two important grants, Rodent Studies of Non-Snord 116 Paternal Ube3a Activation and Pilot Feasibility of an Enzyme Replacement Therapy for AS, both from Dr David Segal’s lab at UC Davis. FAST Canada chose to co-fund these two particular grants because they wanted to focus their first funding
Adult Transition: Meet Juli & Tracy
Juli DelMonego is mom to 3 sons, and her 32 year old daughter Marina with AS. Juli started early learning about disability rights, researching Special Education laws at the FSU law library in the pre-internet days. She advocated for children with disabilities, and the University of FL genetics program diagnosing AS, before the Florida Cabinet
Bienvenue FAST France
FAST is proud to announce the newest addition to its global family: FAST France. Charlotte Prestat and Anthony Moisan, the founders of FAST France, have three children. After receiving a diagnosis of Angelman syndrome in 2017 for their middle daughter Héloïse, the two science-minded engineers researched as much as they could on the syndrome. Their
Global Angelman Syndrome Registry moves platform to QUT
The Global Angelman Syndrome Registry (Registry) had some downtime this week while the platform was moved to the Division of Research and Innovation at QUT (Queensland University of Technology). The move will mean there is a much larger team allowing new functions and materials available more quickly, making the Registry more user friendly for over 1,400 participants in 65 countries and providing new users with
FAST funds pioneering infrastructure grant
FAST is thrilled to announce a grant to our continued partners and renowned scientists dedicated to advancing therapeutics for Angelman syndrome – David Segal, Ph.D., Jill Silverman, Ph.D., and the team at the University of California, Davis. This grant provides the funding to build a lab devoted to Angelman syndrome (AS) research, establishing an infrastructure
FAST update on the impact of Covid-19
While the world as we know it has changed, abruptly and dramatically, we at FAST want you to know that we are here and we continue to move forward in our mission to cure Angelman syndrome. What COVID-19 precautions should parents of children with Angelman syndrome be taking? Although individuals with Angelman syndrome are
Webinar on the KIK-AS Clinical Trials of GTX-102
Additional details on the clinical trials for GTX-102 are available at the link below: https://clinicaltrials.gov/ct2/show/NCT04259281 – A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome (KIK-AS)
Webinar on GTX-102, an investigational antisense oligonucleotide for the treatment of Angelman syndrome
FAST thanks GeneTx Biotherapeutics and Dr. Scott Stromatt for offering insight on GTX-102, the investigational antisense oligonucleotide for the treatment of Angelman syndrome. A recording of this webinar is available below. GeneTx intends to have additional details about the upcoming trial (inclusion/exclusion criteria, protocol, etc.) posted to ClinicalTrials.gov by February 15th and will hold
